PF-Atlas › Clinical Trials › NCT02538536

A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis

PBI4050 · Phase 2

Registry ID

NCT02538536

Phase

Phase 2

Status

Completed

Drug / intervention

PBI4050

Sponsor

Liminal BioSciences Ltd.

Start

2015-07

About this trial

PBI4050 is evaluated in NCT02538536, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Liminal BioSciences Ltd.. Current status: Completed.

View NCT02538536 on ClinicalTrials.gov →

Explore related

All PBI4050 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT02538536 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.